Treatment with recombinant human bone morphogenetic protein 7 leads to a transient induction of neutralizing autoantibodies in a subset of patients

BACKGROUND: Recombinant human bone morphogenetic protein 7 (rhBMP7) is applied for treatment of bone fractures, especially tibial non-unions. Its application may induce autoantibodies (aAB) affecting the targeted and endogenous signaling pathways and in turn negatively impact treatment efficacy. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuette, Andrea, Moghaddam, Arash, Seemann, Petra, Duda, Georg N., Schmidmaier, Gerhard, Schomburg, Lutz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007422/
https://www.ncbi.nlm.nih.gov/pubmed/27617228
http://dx.doi.org/10.1016/j.bbacli.2016.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007422/
https://www.ncbi.nlm.nih.gov/pubmed/27617228
http://dx.doi.org/10.1016/j.bbacli.2016.08.001

Ejemplares similares